PTEN and glioblastoma: These findings spurred the UCLA group to design an important, molecularly focused clinical study, published in this issue of PLoS Medicine [32], to analyze the effect of rapamycin in a subset of patients with recurrent GBM in whom activity of the tumor suppressor PTEN was absent.